Even with discussions about artificial intelligence (AI) becoming part of everyday life, it can sometimes still be difficult to see the practical application of these technologies in our da
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh